Shiseido Q1
This article was originally published in The Rose Sheet
Executive Summary
Japanese cosmetics manufacturer worked to achieve sales volume in the domestic business "by invigorating sales activities" through a focus on the sales counter and concentrating investments on core lines, Shiseido says. In toiletries, value-oriented marketing program was implemented to achieve market leading position, firm adds. Sales were negatively-impacted by recession in Japan, SARS outbreak and a slowdown in the U.S. and European economies. Sales for the first quarter were $1.18 bil. (¥120=$1), but percentage fluctuation between the first quarter period a year ago was not disclosed. In the first half 2002, sales were $2.44 bil...
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.